BI
Boehringer Ingelheim Venture Fund
Corporate VCActiveBoehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.
56
Investments
5
Exits
$500M
AUM
8.9%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Boehringer Ingelheim Venture Fund.
Investment Thesis & Strategy
Boehringer Ingelheim Venture Fund invests in various stages of companies with groundbreaking therapeutic approaches and technologies. As a CVC, they likely focus on companies that align with Boehringer Ingelheim's strategic interests within the healthcare and biotechnology sectors.
Notable Exits
CompanyTypeYearValue / Acquirer
AM-PharmaAcquisition2023$2.1B
VaximmAcquisition2023—
Sunstone TherapeuticsAcquisition2021—
Rigel PharmaceuticalsIPO2013—
SequellaAcquisition2012—
Frequently Asked Questions
Boehringer Ingelheim Venture Fund focuses on Series A, Series B stage investments.